Skip to main content
. 2013 Jun 24;2(1):276. doi: 10.1186/2193-1801-2-276

Table 2.

Clinicopathological characteristics of breast cancer cases in the SBSP

Characteristics 1st round screening 2nd round screening Total
No. of cases Interval cases (N, %) No. of cases Interval cases (N, %) No. of cases Interval cases (N, %)
Overall 51 11 (21.6) 13 2 (15.4) 64 13 (20.3)
Age group
 40- 6 0 3 0 9 0
 50- 25 7 (28.0) 3 1 (33.3) 28 8 (28.6)
 60- 16 3 (18.8) 6 1 (16.7) 22 4 (18.2)
 70- 4 1 (25.0) 1 0 5 1 (20.0)
Pathological type
 DCIS 8 2 (25.0) 0 0 8 2 (25.0)
 DCIS with micro-invasive 5 1 (20.0) 2 0 7 1 (14.3)
 IDC 34 6 (17.7) 9 1 (11.1) 43 7 (16.3)
 Special types 3 2 (66.7) 2 1 (50.0) 5 3 (60.0)
Size (mm)
 DCIS 13 3 (23.1) 3 0 16 3 (18.8)
 < 20 12 3 (25.0) 5 2 (40.0) 17 5 (29.4)
 20- 23 4 (17.4) 4 0 27 4 (14.8)
 50- 2 1 (50.0) 0 0 2 1 (50.0)
Axillary lymph node status
 Negative 40 10 (25.0) 12 2 (16.7) 52 12 (23.1)
 Positive 10 1 (10.0) 0 0 10 1 (10.0)
Stage
 DCIS a 13 3 (23.1) 3 0 16 3 (18.8)
 I 15 3 (20.0) 8 2 (25.0) 23 5 (21.7)
 IIA 14 3 (21.4) 1 0 15 3 (20.0)
 IIB 6 1 (16.7) 0 0 6 1 (16.7)
 III-IV 2 1 (50.0) 0 0 2 1 (50.0)
ER status
 Positive 35 7 (20.0) 9 2 (22.2) 44 9 (20.5)
 Negative 13 4 (30.8) 3 0 16 4 (25.0)
PgR status
 Positive 30 4 (13.3) 9 2 (22.2) 39 6 (15.4)
 Negative 18 7 (38.9) 3 0 21 7 (33.3)

a both DCIS and DCIS with micro-invasive;

Missing values were excluded from the analysis (1 for pathological type, 2 for tumor size, axillary lymph node status and stage, 4 for ER and PgR status).

Abbreviations: DCIS ductal carcinoma in situ, IDC invasive ductal carcinoma, ER estrogen receptor, PgR progesterone receptor.